Urs Rohner Acquires 473 Shares of GlaxoSmithKline plc (GSK) Stock

AIDS Emerges From Behind The Veil In Pakistan

Guidance for 2017 adjusted earnings per share growth was maintained at three to five per cent after it was lowered earlier this year. The fund purchased 13,074 shares of the pharmaceutical company's stock, valued at approximately $531,000. FMR LLC grew its holdings in GlaxoSmithKline PLC by 5.9% in the second quarter. 1,120,326 shares of the company's stock traded hands. Hamilton Point Investment Advisors LLC now owns 36,956 shares of the pharmaceutical company's stock worth $1,594,000 after buying an additional 1,400 shares in the last quarter. Hamilton Point Investment Advisors LLC raised its stake in shares of GlaxoSmithKline PLC by 3.9% in the third quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company's stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company's stock worth $338,377,000 after purchasing an additional 322,700 shares during the last quarter. At the time of writing, the stock had slid down -6.13% since the open.

GSK saw strong demand for HIV drugs and more demand for new respiratory drugs, while the failure of generic companies to win United States approval so far for copies of lung inhalant Advair also boosted profits. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company's stock worth $194,521,000 after acquiring an additional 833,501 shares during the period. Citigroup Inc. reaffirmed a "buy" rating on shares of GlaxoSmithKline PLC in a research note on Monday, November 7th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the company. Finally, Investec restated a "buy" rating and issued a GBX 1,800 ($23.75) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th.

TRADEMARK VIOLATION NOTICE: This story was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States & worldwide copyright law.

GlaxoSmithKline plc (NYSE:GSK)'s stock has performed at 5.12% year to date.

GlaxoSmithKline plc (LON:GSK) last announced its quarterly earnings data on Wednesday, October 25th. Leerink Swann analyst S. Fernandez now anticipates that the pharmaceutical company will post earnings of $2.84 per share for the year, down from their previous forecast of $2.85. The stock has a market cap of $98.93 billion, a PE ratio of 39.22 and a beta of 1.03. The company's 50-day moving average price is $40.52 and its 200-day moving average price is $41.51. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.53. UBS AG set a GBX 1,600 ($21.11) price target on shares of GlaxoSmithKline plc and gave the company a "neutral" rating in a research report on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC's dividend payout ratio (DPR) is now 1,533.33%. The firm had revenue of GBX 784.30 billion for the quarter. Jefferies Group reaffirmed a "buy" rating on shares of GlaxoSmithKline PLC in a research note on Tuesday.

Glaxosmithkline has declared its interest in Pfizer's $15 billion consumer healthcare business in what could be its first big acquisition under Emma Walmsley. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related:

Comments


Other news